Arkansas Supreme Court struck down a $1.2 billion judgement against Johnson & Johnson over the marketing of antipsychotic drug, Risperdal. Arkansas claimed J&J “didn’t properly communicate the antipsychotic’s risks and marketed it for off-label use.”
The Arkansas Supreme Court “ruled that Arkansas improperly sued J&J and its Janssen subsidiary under a law that applies to healthcare facilities rather than pharma companies.”